FOSUN HEALTH Logo

Multiple Myeloma Causes

catalogue

Multiple Myeloma Causes

Multiple Myeloma Causes

Multiple myeloma has no single cause that explains a given patient, and for most people no cause will be identified at all. What is known is a set of factors that raise the probability of the disease in a population: a preceding monoclonal protein, increasing age, male sex, particular ancestry groups, a family history, and exposure to ionising radiation and some agricultural or industrial chemicals. None of these is a cause in the sense of being necessary or sufficient, and none of them explains why this patient developed the disease at this time.

The precursor that is not yet the disease

The clearest sequence in myeloma begins before the diagnosis. A monoclonal protein appears without any other abnormality, and in a small proportion of people it progresses over years, first to a form with more protein but still no damage, and then to active disease:

  • Monoclonal gammopathy of undetermined significance — a small protein with fewer than ten percent plasma cells and no damage. It is common in older adults, it is not treated, and a small proportion progress each year.
  • Smouldering myeloma — a higher protein level or a higher plasma cell proportion, still without damage. A proportion of these progress more quickly than the first group, which is why the monitoring interval is set according to the numbers.
  • Why the progression happens is not fully understood — the plasma cell acquires further changes over time, and the chromosome findings present at each stage give some indication of how far along that process a patient is.
  • What follows from this is a follow-up rather than a treatment — monitoring at intervals defined by the protein level and the chromosome findings, aimed at starting treatment when damage appears or is about to appear, not before.

Age, sex and population patterns

The patterns in who develops myeloma are consistent across registries, and they are worth stating plainly because patients often read more into them than the evidence supports:

  • Age — the disease is uncommon below the age of forty and most cases are diagnosed after sixty. It is therefore a disease in which the age of the patient shapes the treatment decisions.
  • Sex — men are affected somewhat more often than women, for reasons that are not established.
  • Ancestry — the recorded incidence is higher in people of African ancestry and lower in most Asian populations, differences that are consistent enough to appear in international registry data. They are population-level observations, and they say nothing about any individual.
  • Family history — a modest increase in risk for first-degree relatives, and clustering within some families, which indicates a genetic component rather than an inherited disease in the usual sense.
  • What these do not do — they do not identify a cause, and no test is recommended for relatives of an ordinary patient for this reason alone.

Exposures that raise the risk

Environmental causes are difficult to establish in a disease that is uncommon and appears decades after exposure. The evidence is strongest for a small number of exposures, and it is worth being precise about which:

  • Ionising radiation — the clearest association, observed in people exposed to higher doses, including survivors of radiation incidents and recipients of radiation treatment. Diagnostic imaging at ordinary doses is not established as a cause, which is a reason not to fear necessary imaging but also not to request unnecessary imaging.
  • Agricultural chemicals — studies of farming populations have reported an association with certain pesticides and herbicides, though individual exposures are difficult to quantify and results vary between studies.
  • Organic solvents and petroleum products — including benzene, which is also an established cause of leukaemia, and other solvents studied in industrial settings.
  • Occupational patterns — reported in some groups with sustained exposure, such as firefighters and some industrial workers, but these findings are difficult to separate from the other exposures such groups have.
  • What follows for a patient — almost nothing practical. Knowledge of exposure does not change the treatment, and no monitoring programme is recommended on the basis of exposure alone.

Chronic inflammation and immune stimulation

Myeloma is a disease of the immune system, and the observation that chronic immune stimulation accompanies it more often than expected has both a simple explanation and an important limitation:

  • Monoclonal proteins are commoner in people with chronic inflammatory or autoimmune conditions, including rheumatoid arthritis and some other connective tissue diseases.
  • It is difficult to establish cause because the finding is itself discovered by the same kinds of blood tests that such patients have repeatedly — an association with surveillance as much as with biology.
  • Obesity is associated with a modestly increased risk, and it is also associated with many of the inflammatory conditions above; the mechanisms proposed overlap.
  • Chronic infection has been suggested as a contributor through sustained immune stimulation, and while this is plausible, the evidence does not support attributing a patient's disease to a particular past infection.
  • The practical conclusion is that an associated condition may explain why a monoclonal protein was found on a blood test, but it does not explain why the disease progressed, and it does not change the treatment.

Factors that do not cause myeloma

Patients regularly ask whether something they did, or were exposed to, caused the disease. For the factors below, the evidence does not support a causal role, and saying so is part of giving an honest answer:

  • Smoking — an established cause of many cancers and of leukaemia, but it has not been established as a cause of myeloma. This is unusual among cancers and worth stating precisely rather than folding it into general advice.
  • Alcohol — not established as a cause.
  • Diet and body weight — obesity is associated with a modest increase in risk, but no single food, food group or dietary pattern has been shown to cause or prevent the disease.
  • Stress and emotional circumstances — no evidence of a causal role. Suggesting otherwise places blame where none belongs.
  • Mobile phones, hair dyes and electromagnetic fields — commonly studied and repeatedly not confirmed; studies that once suggested a link have not been reproduced.
  • Inheritance in the ordinary sense — most patients have no affected relative, and no predictive genetic testing is recommended for family members outside an identified familial syndrome.

Who is at higher risk, and who is not

Risk in this disease is a matter of degree rather than of presence or absence, and the distinction matters for what should be done about it:

  • Higher risk — a known monoclonal gammopathy or smouldering myeloma, which is the group for which follow-up is actively recommended because it is the group in which progression can be detected before damage.
  • Modestly higher risk — increasing age, male sex, a first-degree relative with the disease, obesity, and a history of substantial exposure to ionising radiation or to the agricultural and industrial chemicals described above.
  • Not at measurably higher risk — people with none of those features, which is the great majority of adults.
  • The difference in what is done — for the first group there is a defined follow-up schedule; for the others there is no recommended testing, and the reasonable approach is to have persistent bone pain, anaemia or reduced kidney function explained rather than assumed.
  • What to do with a family history — mention it at any assessment, since it may be relevant, and ask whether any monitoring is warranted in your case. For most families the answer is no, and that answer is worth hearing explicitly.

Frequently Asked Questions

Is myeloma hereditary?

Not in the ordinary sense. Most people who develop myeloma have no affected relative, and no gene has been identified that carries the disease from parent to child in a predictable way. What exists is a modest increase in risk for first-degree relatives and occasional clustering within families, which indicates that inherited factors contribute in some cases without determining the outcome. For a family in which one person has the disease, no genetic test and no monitoring programme is recommended for the relatives — mention the family history at any future assessment, but there is no reason for relatives to be tested.

Did something I was exposed to at work cause this?

For the great majority of patients, no occupational exposure can be identified, and it is not possible to attribute an individual case to a particular exposure even where a population-level association exists. The associations that are reasonably established are ionising radiation at higher doses and some agricultural or industrial chemicals, including certain pesticides, herbicides and organic solvents. Understanding this does not change your treatment or your follow-up, and it is worth being cautious about drawing a direct conclusion about your own case.

If I have MGUS, what is the chance it will become myeloma?

The chance is small for any one person, and it is why MGUS is monitored rather than treated. Each year a small proportion of cases progress, and over many years a meaningful minority do — which is why follow-up continues indefinitely rather than being concluded after one normal test. The interval between checks is set by the size and type of the protein and by the blood count, and a rise in the protein, a fall in the haemoglobin or a new symptom is what prompts a closer look rather than waiting for the next scheduled visit.

Does eating a particular diet, or taking a supplement, reduce the risk?

There is no diet, supplement or lifestyle measure that has been shown to prevent myeloma or to stop MGUS from progressing. Where diet and supplements do matter is during treatment, and there they matter in a specific way: adequate protein and calories to maintain weight, food safety precautions while the immune system is suppressed, and avoidance of supplements that interact with treatment. Any supplement should be discussed with the treating team rather than added on the basis that it is natural, because some interfere with the drugs and some are marketed without evidence.

Ask what your own findings imply

Send the date and value of any monoclonal protein measurement, the plasma cell proportion from the marrow if it has been taken, the blood count, calcium and creatinine, and the chromosome findings. Our haematology team will return a written assessment within 48 hours of the file being complete, including whether monitoring or treatment is appropriate.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*